← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Kephera Diagnostics, Llc
Framingham, MA
$22,422,843
Total funding
19
Grants
Funding over time
peak $5.3M · FY2017–25$10M$7.5M$5M$2.5M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,119,593 · 18
HHS (Other)$303,250 · 1
By mechanism
R44$14,716,029 · 6
R43$4,506,856 · 8
N44$1,999,961 · 1
N43$600,000 · 2
N01$599,997 · 2
Investigators at Kephera Diagnostics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
TOPIC 388: IN VITRO DIAGNOSTIC FOR THE LIVER FLUKES OPISTHORCHIS VIVERRINI AND CLONORCHIS SINENSI$1,999,961
N44 · FY2021 · CA
Hybrid ELISA: Simple and specific one-tier assay for Lyme disease$1,025,000
R44 · FY2023 · AI
Hybrid ELISA: Simple and specific one-tier assay for Lyme disease$1,025,000
R44 · FY2024 · AI
Point-of-care diagnostic test for T. cruzi (Chagas) infection$1,020,000
R44 · FY2023 · AI
Point-of-care diagnostic test for T. cruzi (Chagas) infection$1,015,000
R44 · FY2024 · AI
Point-of-care diagnostic test for T. cruzi (Chagas) infection$1,015,000
R44 · FY2025 · AI
Biomarker-Based Test of Cure for Chagas Disease$1,014,999
R44 · FY2023 · AI
Biomarker-Based Test of Cure for Chagas Disease$1,013,849
R44 · FY2024 · AI
Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients$1,000,000
R44 · FY2024 · AI
Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling$1,000,000
R44 · FY2020 · AI
Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients$999,008
R44 · FY2023 · AI
Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling$989,300
R44 · FY2021 · AI
Peptide-based ELISA for laboratory diagnosis of sarcoidosis$978,191
R44 · FY2025 · HL
Biomarker-Based Test of Cure for Chagas Disease$906,016
R44 · FY2025 · AI
Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients$876,394
R44 · FY2025 · AI
Hybrid ELISA: Simple and specific one-tier assay for Lyme disease$714,666
R44 · FY2025 · AI
Diagnostic assay for congenital Chagas disease$303,250
R43 · FY2024 · AI
MiCRIA: Two-minute rapid assay platform for point-of-care diagnosis$303,250
R43 · FY2024 · JG
Diagnostic assay for congenital Chagas disease$303,250
R43 · FY2025 · AI
Development of an ELISA for serosurveillance of human hookworm$300,000
R43 · FY2023 · AI